Drug Profile
GCAN 101
Alternative Names: GCAN101Latest Information Update: 13 Sep 2015
Price :
$50
*
At a glance
- Originator GammaCan International
- Class Antineoplastics; Immunoglobulins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 20 Dec 2005 GammaCan has entered into a research and licensing agreement with Tel Hashomer Medical Research Infrastructure and Services Ltd
- 27 Jul 2005 Phase-II clinical trials in Cancer in Israel (IV)
- 17 Mar 2005 Preclinical trials in Cancer in Israel (unspecified route)